Yeni bir CAR-T terapisi olan HSP-CAR30, CD30 pozitif lenfoma t\u00fcrlerinde \u00e7\u0131\u011f\u0131r a\u00e7an bir geli\u015fme olarak g\u00fcndeme geldi. Barselona\u2019daki Sant Pau Ara\u015ft\u0131rma Enstit\u00fcs\u00fc (IR Sant Pau), Sant Pau Hastanesi ve Josep Carreras L\u00f6semi Ara\u015ft\u0131rma Enstit\u00fcs\u00fc i\u015f birli\u011fi ile geli\u015ftirilen bu yenilik\u00e7i tedavi, \u00f6zellikle Hodgkin lenfoma ve baz\u0131 T h\u00fccreli lenfoma t\u00fcrlerinde bulunan CD30 proteini hedef al\u0131narak \u00fcretildi. Kanser tedavisinde, \u00f6zellikle standart kemoterapi ve di\u011fer y\u00f6ntemlerin ba\u015far\u0131s\u0131z kald\u0131\u011f\u0131 diren\u00e7li hastal\u0131klar i\u00e7in umut vadeden HSP-CAR30, imm\u00fcn yan\u0131t\u0131 uzun s\u00fcre destekleyen haf\u0131za T h\u00fccrelerinin geni\u015flemesini te\u015fvik etme kapasitesiyle dikkat \u00e7ekiyor.<\/p>\n
Hodgkin lenfoma ve CD30 pozitif di\u011fer lenfomalar\u0131n tedavisi, diren\u00e7li veya tekrarlayan vakalarda onkologlar i\u00e7in her zaman zorluk olu\u015fturdu. CAR-T terapilerinin baz\u0131 hematolojik kanserlerde, \u00f6zellikle B h\u00fccresi malignitelerinde devrim yaratmas\u0131na kar\u015f\u0131n, CD30 pozitif lenfomalar \u00fczerindeki etkinlikleri s\u0131n\u0131rl\u0131 kal\u0131yordu. Bunun sebeplerinden biri, modifiye T h\u00fccrelerinin v\u00fccutta k\u0131sa s\u00fcrede yok olmas\u0131 ve hastal\u0131\u011f\u0131n n\u00fcks etme ihtimalinin y\u00fcksek olmas\u0131yd\u0131. Ayr\u0131ca, bu lenfoma t\u00fcrleri \u00fczerine yap\u0131lan klinik \u00e7al\u0131\u015fmalar\u0131n azl\u0131\u011f\u0131 tedavi se\u00e7eneklerinin geni\u015flemesini de k\u0131s\u0131tlamaktayd\u0131. HSP-CAR30, bu problemlere yenilik\u00e7i \u00e7\u00f6z\u00fcmler getiren bir yakla\u015f\u0131m olarak \u00f6ne \u00e7\u0131k\u0131yor.<\/p>\n
HSP-CAR30\u2019un tasar\u0131m\u0131nda, T h\u00fccrelerinin i\u015flevselli\u011fini ve dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 art\u0131rmaya y\u00f6nelik ileri genetik m\u00fchendisli\u011fi teknikleri kullan\u0131ld\u0131. Terapide CD30 antijeninin stabil bir epitopu hedef al\u0131nd\u0131; bu sayede t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden ka\u00e7mak i\u00e7in bu proteini dola\u015f\u0131ma b\u0131rakma stratefi b\u00fcy\u00fck \u00f6l\u00e7\u00fcde engellendi. Tedavi \u00fcretim s\u00fcrecinde, IL-7, IL-15 ve IL-21 gibi sitokinler eklenerek T h\u00fccrelerinin daha az farkl\u0131la\u015fm\u0131\u015f, haf\u0131za benzeri alt gruplar\u0131n\u0131 geli\u015ftirme ve \u00e7o\u011falma kapasitesi desteklendi. Bu h\u00fccre alt tipleri, tedavi sonras\u0131 daha uzun s\u00fcreli ba\u011f\u0131\u015f\u0131kl\u0131k korumas\u0131 sa\u011fl\u0131yor.<\/p>\n
Faz I klinik denemede, tekrarlayan ya da diren\u00e7 g\u00f6steren klasik Hodgkin lenfoma veya CD30 pozitif T h\u00fccreli lenfoma hastalar\u0131ndan olu\u015fan 10 ki\u015filik bir grup HSP-CAR30 tedavisi ald\u0131. Bu hastalarda %100\u2019l\u00fck genel yan\u0131t oran\u0131 elde edilmesi; \u00f6nceden \u00e7ok say\u0131da tedavi alm\u0131\u015f hastalarda nadiren g\u00f6r\u00fclen bir ba\u015far\u0131 olarak de\u011ferlendirildi. Kat\u0131l\u0131mc\u0131lar\u0131n yar\u0131s\u0131 tam remisyona ula\u015ft\u0131 ve g\u00f6r\u00fcnt\u00fcleme ile hastal\u0131k \u00f6l\u00e7\u00fclebilir seviyede tespit edilemedi. Ayr\u0131ca, doz s\u0131n\u0131rlay\u0131c\u0131 toksisitelerin ya\u015fanmamas\u0131 bu yeni terapinin g\u00fcvenlik profilini de g\u00fc\u00e7lendirdi.<\/p>\n
\u0130mm\u00fcnoterapide tedavi sonras\u0131 yan\u0131tlar\u0131n kal\u0131c\u0131l\u0131\u011f\u0131 kritik \u00f6neme sahiptir. Ortalama \u00fc\u00e7 y\u0131l s\u00fcren takipte kurumaya ula\u015fan hastalar\u0131n %60\u2019\u0131, remisyona girdikten sonra hastal\u0131k n\u00fcks\u00fc ya\u015famadan izlenebildi. Bu uzun s\u00fcreli koruma, hastalar\u0131n kan dola\u015f\u0131m\u0131nda HSP-CAR30 T h\u00fccrelerinin kal\u0131c\u0131 bir \u015fekilde bulunmas\u0131yla yak\u0131ndan ili\u015fkilendirildi. N\u00f6rotoksisite a\u00e7\u0131s\u0131ndan da olumlu sonu\u00e7lar g\u00f6zlendi; a\u011f\u0131r n\u00f6rolojik yan etkiler ya\u015fanmazken, hafif dereceli sitokin sal\u0131n\u0131m sendromu nadiren ve y\u00f6netilebilir \u015fekilde geli\u015fti.<\/p>\n
Tedavi aktif hale geldi\u011finde olu\u015fan h\u00fccresel profil incelendi\u011finde, merkezi haf\u0131za (TCM) ve k\u00f6k h\u00fccre benzeri haf\u0131za (TSCM-benzeri) T h\u00fccrelerinin art\u0131\u015f g\u00f6sterdi\u011fi saptand\u0131. Bu daha az farkl\u0131la\u015fm\u0131\u015f alt gruplar, y\u00fcksek \u00e7o\u011falma kapasiteleri ve uzun \u00f6m\u00fcrleriyle biliniyor. \u0130\u015fte bu \u00f6zelliklerin, HSP-CAR30 tedavisinden kaynaklanan uzun vadeli faydalar\u0131n temelinde yatt\u0131\u011f\u0131 d\u00fc\u015f\u00fcn\u00fcl\u00fcyor. B\u00f6ylece tedavi, y\u00fcksek etkinlikli ve kal\u0131c\u0131 bir imm\u00fcn savunma mekanizmas\u0131 olu\u015fturarak, hastal\u0131\u011f\u0131n tekrarlama riskini azalt\u0131yor.<\/p>\n
Ara\u015ft\u0131rmay\u0131 y\u00f6neten uzmanlar, CD30 epitopunun dikkatli se\u00e7imi ve \u00fcretim s\u0131ras\u0131nda erken a\u015fama T h\u00fccrelerinin korunmas\u0131n\u0131n ba\u015far\u0131n\u0131n anahtar\u0131 oldu\u011funu vurguluyor. Dan\u0131\u015fman hematolog ve ortak ara\u015ft\u0131rmac\u0131 Dr. Ana Caballero, bu olumlu bulgular\u0131n daha geni\u015f \u00e7apl\u0131 denemelerle teyit edilmesi durumunda, tedavi y\u00f6nteminde k\u00f6kl\u00fc bir d\u00f6n\u00fc\u015f\u00fcm ya\u015fanaca\u011f\u0131n\u0131 belirtiyor. \u00d6zellikle \u00f6nceden tedavi se\u00e7eneklerinin s\u0131n\u0131rl\u0131 oldu\u011fu hastalar i\u00e7in bu geli\u015fmenin yeni bir umut \u0131\u015f\u0131\u011f\u0131 olaca\u011f\u0131n\u0131 dile getiriyor.<\/p>\n
Ba\u015far\u0131l\u0131 Faz I \u00e7al\u0131\u015fmas\u0131n\u0131n ard\u0131ndan, \u00e7al\u0131\u015fma Faz II a\u015famas\u0131na ta\u015f\u0131nd\u0131. Hasta say\u0131s\u0131 32\u2019ye \u00e7\u0131kar\u0131ld\u0131 ve daha fazla veri elde etmek amac\u0131yla ek 10 hasta programa dahil edildi. Yay\u0131nlanan \u00f6n veriler, kat\u0131l\u0131mc\u0131lar\u0131n %55\u2019inden fazlas\u0131nda tam remisyonun g\u00f6zlendi\u011fini g\u00f6steriyor. Bu sonu\u00e7lar, HSP-CAR30\u2019un geni\u015f \u00e7apta uygulanabilirli\u011fini destekleyerek, onay s\u00fcreci ve tedavi optimizasyonu i\u00e7in sa\u011flam bir temel olu\u015fturuyor.<\/p>\n
CAR-T h\u00fccre tedavisinin temel mekanizmas\u0131, hastadan al\u0131nan T lenfositlerin genetik olarak modifiye edilip, t\u00fcm\u00f6r h\u00fccrelerinin y\u00fczeyindeki \u00f6zg\u00fcl antijenleri hedef alacak bi\u00e7imde yap\u0131land\u0131r\u0131lmas\u0131d\u0131r. HSP-CAR30 geli\u015ftirilirken, antijen hedefleme hassasiyeti ve sitokin destekli \u00fcretim s\u00fcreci iyile\u015ftirildi. B\u00f6ylece, \u00f6nceki tetkiklerde kar\u015f\u0131la\u015f\u0131lan T h\u00fccre yorgunlu\u011fu ve t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131ktan ka\u00e7ma ters etkileri \u00f6nemli oranda giderildi.<\/p>\n
Tedavi \u00fcretim protokol\u00fcnde interl\u00f6kin-21\u2019in IL-7 ve IL-15 ile kombine kullan\u0131lmas\u0131 ayr\u0131 bir \u00f6neme sahip. IL-21, uzun \u00f6m\u00fcrl\u00fc haf\u0131za T h\u00fccrelerinin olu\u015fumunu te\u015fvik ederek, HSP-CAR30\u2019un \u00fcretim a\u015famas\u0131n\u0131 di\u011fer CAR-T y\u00f6ntemlerinden ay\u0131r\u0131yor. Bu sitokin kar\u0131\u015f\u0131m\u0131, hastalarda uzun s\u00fcreli imm\u00fcn g\u00f6zetimi m\u00fcmk\u00fcn k\u0131lan T h\u00fccre fenotipini olu\u015fturuyor ve b\u00f6ylelikle hastal\u0131k n\u00fcks\u00fcn\u00fcn engellenmesi hedefleniyor.<\/p>\n
\u00dcretim ve kalite kontrol s\u00fcre\u00e7leri, modifiye T h\u00fccrelerin canl\u0131l\u0131\u011f\u0131n\u0131 ve i\u015flevselli\u011fini sa\u011flamak \u00fczere titizlikle y\u00f6netiliyor. CAR30 \u00fcretimi kalite kontrol direkt\u00f6r\u00fc Dr. Laura Escrib\u00e0, ama\u00e7lar\u0131n\u0131n hastalara sadece ge\u00e7ici bir fayda sunmak de\u011fil, lenfoman\u0131n tekrar etmesi durumunda h\u0131zl\u0131 yan\u0131t verebilecek uzun \u00f6m\u00fcrl\u00fc bir h\u00fccresel koruma sa\u011flamak oldu\u011funa dikkat \u00e7ekiyor. Bu y\u00fcksek kalite standartlar\u0131, tedavinin hem g\u00fcvenli\u011fini hem de klinik ba\u015far\u0131s\u0131n\u0131 destekleyen temel unsurlar aras\u0131nda.<\/p>\n
HSP-CAR30 terapisi, Josep Carreras L\u00f6semi Vakf\u0131 ve Josep Carreras L\u00f6semi Ara\u015ft\u0131rma Enstit\u00fcs\u00fc ba\u015fta olmak \u00fczere pek \u00e7ok kurulu\u015ftan \u00f6nemli maddi destek ald\u0131. \u201cDurmaks\u0131z\u0131n H\u00fccre Fabrikas\u0131\u201d kampanyas\u0131 bu kaynaklar\u0131n \u00f6nemli bir k\u0131sm\u0131n\u0131 olu\u015fturarak, ileri d\u00fczey h\u00fccre \u00fcretim \u00fcnitelerinin kurulmas\u0131n\u0131 ve ilk hastalara verilecek dozlar\u0131n haz\u0131rlanmas\u0131n\u0131 m\u00fcmk\u00fcn k\u0131ld\u0131. Ayr\u0131ca Avrupa \u00e7ap\u0131nda kamu ve \u00f6zel ara\u015ft\u0131rma fonlar\u0131n\u0131n katk\u0131s\u0131, bu \u00f6nc\u00fc \u00e7al\u0131\u015fman\u0131n \u00e7eviri ara\u015ft\u0131rma ekosistemini g\u00fc\u00e7lendirdi.<\/p>\n
Bu \u00f6nc\u00fcl Avrupa \u00e7al\u0131\u015fmas\u0131, 2024 Amerikan Hematoloji Derne\u011fi (ASH) toplant\u0131s\u0131nda, ba\u015far\u0131l\u0131 Faz I sonu\u00e7lar\u0131 ve \u00f6nemli Faz II verileriyle dikkat \u00e7ekti. Sadece do\u011frudan t\u00fcm\u00f6r hedeflemenin \u00f6tesinde, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi haf\u0131zas\u0131n\u0131n mod\u00fclasyonu yoluyla uzun s\u00fcreli remisyonun sa\u011flanmas\u0131 paradigmas\u0131n\u0131 benimseyen yeni CAR-T geli\u015ftirmenin \u00f6rne\u011fini sundu. B\u00f6ylece, hastalar i\u00e7in hem etkin hem de dayan\u0131kl\u0131 tedavi \u00e7\u00f6z\u00fcmleri sunma yolunda \u00f6nemli bir model olu\u015fturuldu.<\/p>\n
Genetik m\u00fchendislik, imm\u00fcnoloji ve geli\u015fmi\u015f \u00fcretim teknolojilerinin kesi\u015fim noktas\u0131nda yer alan HSP-CAR30, CD30 pozitif lenfoma tedavisinde yenilik\u00e7ili\u011fin yeni simgesi haline geldi. Gelecekte yap\u0131lacak daha b\u00fcy\u00fck \u00f6l\u00e7ekli denemeler benzer ba\u015far\u0131l\u0131 sonu\u00e7lar\u0131 do\u011frulay\u0131p bu tedavi y\u00f6ntemini tescillerse, diren\u00e7li veya tekrarlayan hastalar i\u00e7in hayati \u00f6nem ta\u015f\u0131yan bu alan\u0131n tedavi perspektifi k\u00f6kl\u00fc bi\u00e7imde de\u011fi\u015febilir. Bu geli\u015fme, kanser imm\u00fcnoterapisinde oyunculara uzun s\u00fcreli, \u00f6zelle\u015ftirilmi\u015f ve y\u00fcksek etkinlik vaat eden yeni bir sayfa a\u00e7\u0131yor.<\/p>\n
—<\/p>\n
**Ara\u015ft\u0131rma Konusu**: People
\n**Makale Ba\u015fl\u0131\u011f\u0131**: HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma
\n**Haberin Yay\u0131n Tarihi**: 17-Apr-2025
\n**Web References**:
\nhttps:\/\/doi.org\/10.1182\/blood.2024026758
\nhttp:\/\/dx.doi.org\/10.1182\/blood.2024026758
\n**Doi Referans**: 10.1182\/blood.2024026758
\n**Resim Credits**: Josep Carreras Leukaemia Research Institute
\n**Anahtar Kelimeler**: breakthrough cancer immunotherapy, CAR-T therapy for refractory lymphoma, CD30-positive lymphoma treatment, challenges in lymphoma management, durable immune responses in lymphoma, engineered T cells in oncology, Hodgkin lymphoma innovative therapies, HSP-CAR30 clinical trial outcomes, memory T cell expansion, refractory cancer treatment advancements, Sant Pau Research Institute contributions, targeted therapies for hematologic cancers<\/p>\n","protected":false},"excerpt":{"rendered":"
Yeni bir CAR-T terapisi olan HSP-CAR30, CD30 pozitif lenfoma t\u00fcrlerinde \u00e7\u0131\u011f\u0131r a\u00e7an bir geli\u015fme olarak g\u00fcndeme geldi. Barselona\u2019daki Sant Pau Ara\u015ft\u0131rma Enstit\u00fcs\u00fc (IR Sant Pau), Sant Pau Hastanesi ve Josep Carreras L\u00f6semi Ara\u015ft\u0131rma Enstit\u00fcs\u00fc i\u015f birli\u011fi ile geli\u015ftirilen bu yenilik\u00e7i tedavi, \u00f6zellikle Hodgkin lenfoma ve baz\u0131 T h\u00fccreli lenfoma t\u00fcrlerinde bulunan CD30 proteini hedef al\u0131narak…<\/p>\n","protected":false},"author":1,"featured_media":4192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3982,3983,3984,3985,3986],"tmauthors":[],"class_list":{"0":"post-4191","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-car-t-tedavisi-hodgkin-lenfoma-icin-yenilikci-immunoterapi","9":"tag-cd30-pozitif-lenfoma-tedavisinde-genetik-muhendislik-uygulamalari","10":"tag-direncli-ve-tekrarlayan-klasik-hodgkin-lenfoma-tedavi-secenekleri","11":"tag-hafiza-t-hucreleri-destekleyen-car-t-terapileri","12":"tag-il-7-il-15-il-21-sitokin-destekli-kanser-immunoterapisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Refrakter-Lenfoma-Icin-Yenilikci-CAR-T-Tedavisi-1745912723.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4191"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4191\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4192"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4191"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}